11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Vyepti

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Eptinezumab

Eptinezumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.

  2. Vig SJ, Garza J, Tao Y. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache. 2022;00:1–8.

  3. Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase. J Headache Pain. 2024;25(1):10.

  4. EMA. Vyepti Public Assessment Report . [www]. [updated 2021-11-11, cited 2022-10-21].

  5. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365-9.

  6. Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019;106(0):224-238.

  7. EMA. Emgality. CHMP assessment report 2018-09-20.

  8. Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®. Cephalalgia. 2023;43(4):3331024231158083.

  1. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
  2. Vig SJ, Garza J, Tao Y. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache. 2022;00:1–8.
  3. Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase. J Headache Pain. 2024;25(1):10.
  4. EMA. Vyepti Public Assessment Report . [www]. [updated 2021-11-11, cited 2022-10-21].
  5. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365-9.
  6. Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019;106(0):224-238.
  7. EMA. Emgality. CHMP assessment report 2018-09-20.
  8. Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®. Cephalalgia. 2023;43(4):3331024231158083.